Akari Therapeutics plc ADS (NASDAQ: AKTX)
$3.61
+0.1100 ( +3.14% ) 16.6K
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
Market Data
Open
$3.61
Previous close
$3.50
Volume
16.6K
Market cap
$43.91M
Day range
$3.51 - $3.73
52 week range
$1.08 - $5.50
SEC Fillings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 3 | Insider transactions | 2 | Jan 02, 2024 |
| 6-k | Quarterly Reports | 2 | Dec 01, 2023 |
| 6-k | Quarterly Reports | 2 | Nov 16, 2023 |
| 6-k | Quarterly Reports | 53 | Sep 29, 2023 |
| 6-k | Quarterly Reports | 5 | Sep 21, 2023 |
| 6-k | Quarterly Reports | 2 | Sep 05, 2023 |
| 6-k | Quarterly Reports | 2 | Aug 18, 2023 |
| 6-k | Quarterly Reports | 2 | Aug 15, 2023 |
| 6-k | Quarterly Reports | 2 | Aug 02, 2023 |
| 6-k | Quarterly Reports | 2 | Jul 27, 2023 |